Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Injection of HRS-9563 in Subjects With Mild Hypertension: a Randomized, Double-blind, Placebo-controlled Phase I Study.

Inclusion criteria

• Males or infertile women aged 18-65 years (inclusive);
• Body mass index in the range of 19-28 kg/m2 (inclusive);
• Mild primary hypertension, without antihypertensive treatment, with a mean sitting systolic blood pressure ≥ 130 mmHg and ≤ 159 mmHg during screening and baseline, and a mean 24-hour ambulatory systolic blood pressure ≥ 130 mmHg during screening.

Exclusion criteria

• Abnormal daily life rhythm;
• Any blood biochemical indicator during screening or baseline did not meet the standards in the exclusion criteria;
• Secondary hypertension;
• Mean sitting diastolic blood pressure ≥ 100 mmHg;
• Orthostatic hypotension;
• History of type 2 diabetes mellitus or poorly controlled blood glucose;
• Recently received any antihypertensive medications or medications that affect blood pressure.